Vir Biotechnology’s Phase 3 Breakthrough: Elebsiran & Tobevibart Show 48‑Week Success for Chronic Hepatitis Delta
Vir Biotechnology’s Elebsiran‑Tobevibart combo meets Phase 3 endpoints, offering a monthly subcutaneous cure for chronic hepatitis delta and a new hope for HBV‑co‑infected patients.
2 minutes to read



